* Cardio IQ Lab Tests - Save 22% to 57%

Get the Cardio IQ Lipid panel for $8.95 plus save 22% to 57% on Quest Cardio IQ tests with promo code: CardioIQ22. Get your complete cholesterol/lipids test for $8.95 during Cholesterol Awareness Month. Our Cardio IQ™ Lipid Panel test contains 1 test with 6 biomarkers. Cholesterol, Total; HDL Cholesterol; LDL-Cholesterol; Non HDL Cholesterol; Chol/HDLC Ratio; and Triglycerides.

  • Promotion Code:
  • CARDIOIQ22
Apolipoprotein A1 is the primary protein associated with HDL cholesterol. Like HDL cholesterol, increased concentrations are associated with reduced risk of cardiovascular disease.

There are two major forms of Apolipoprotein B, B-100 and B-48. B-100, synthesized in the liver, is the major protein in VLDL, IDL, and LDL cholesterol. B-48, synthesized in the intestines, is essential for the assembly and secretion of chylomicrons. Patients with increased concentrations of Apolipoprotein B are at increased risk of atherosclerosis.

Apolipoprotein A1 is the primary protein associated with HDL cholesterol. Like HDL cholesterol, increased concentrations are associated with reduced risk of cardiovascular disease. Apolipoprotein B-100 is the primary protein associated with LDL cholesterol and other lipid particles. Like LDL cholesterol, increased concentrations are associated with increased risk of cardiovascular disease. The ratio of these two apolipoproteins correlates with risk of cardiovascular disease.

LDL Cholesterol is referred to as the "bad" cholesterol. Interpretive ranges are based on the guidelines of the National Cholesterol Education Program (NCEP).

To assist with control of blood glucose levels, the American Diabetes Association (ADA) has recommended glycated hemoglobin testing (HbA1c) twice a year for patients with stable glycemia, and quarterly for patients with poor glucose control. Interpretive ranges are based on ADA guidelines

An elevated concentration of Homocysteine is an independent risk factor for cardiovascular disease.

Most Popular
Useful in predicting risk of cardiovascular disease.

Most Popular
Insulin is useful in diagnosing hyperinsulinemia in hypoglycemic patients. Hyperinsulinemia may be due to an insulin-producing tumor (insulinoma), syndrome of insulin resistance, or persistent hyperinsulinemic hypoglycemia of infancy.

This is the most common Lipid Panel. Components include those useful in the detection, classification, and monitoring of patients with hyperlipidemia.

Elevated concentrations of Lp(a) are associated with increased risk of coronary artery disease.

There is a correlation between increased risk of premature heart disease with decreasing size of LDL particles. Ion mobility offers the only direct measurement of lipoprotein particle size and concentration for each lipoprotein from HDL3 to large VLDL.

Cardio IQ Lp-PLA2 Activity

Clinical Significance

Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet activating factor Acetylhydrolase, is an inflammatory enzyme that circulates bound mainly to low density lipoproteins and has been found to be localized and enriched in atherosclerotic plaques. In multiple clinical trials, Lp-PLA2 activity has been shown to be an independent predictor of coronary heart disease and stroke in the general population. Measurement of Lp-PLA2 may be used along with traditional cardiovascular risk factor measures for identifying individuals at higher risk of cardiovascular disease events. Clinical management may include beginning or intensifying risk reduction strategies. The activity assay is an enzyme assay run on an automated chemistry platform.


1. Baseline and monitoring of individuals with known CVD (acute and chronic) to determine Rx and compliance. 2. Identify patients with known CVD risk with low omega-3 levels who may be candidates for supplementation/therapy. 3. Monitor patients on omega-3 supplementation/therapy to determine efficacy of treatment. 4. Potential role in risk reduction for non-CVD outcomes-aged related macular degeneration, RA, cancer, etc. (early data).

Measurement of serum 25-OH vitamin D concentrations provide a good index of circulating vitamin D activity in patients not suffering from renal disease. Lower than normal 25-OH vitamin D levels can result from a dietary deficiency, poor abosrption of the vitamin or impaired metabolism of the sterol in the liver. A 25-OH vitamin D deficiency can lead to bone diseases such as rickets and osteomalacia. Above normal levels can lead hypercalcemia. This assay employs liquid chromatography tandem mass spectrometry to independently measure and report the two common forms of 25-hydroxy vitamin D: 25OH D3 - the endogenous form of the vitamin and 25OH D2 - the analog form used to treat 25OH Vitamin D3 deficiency.

Measuring Lipid Subclasses using Ion Mobility

The way most doctors test for heart disease is with a lipid panel. It helps detect what HDL (good) and LDL (bad) cholesterol are, so hopefully you can reduce your risk of a possible cardiac event such as a heart attack. Nearly half of all heart attack patients were found to have no prior risk which would indicate they were heading toward an attack.

Quest Diagnostics offers advanced cardiovascular tests that help provide a more accurate and individualized picture of risk. The tests look beyond just HDL and LDL cholesterol to identify undiagnosed (or additional) risk.

These advanced cardiovascular tests, along with your lipid panel, will provide more information that you and your doctor can use to understand your complete cardiovascular health.

Lipid Subclasses as measured by Ion Mobility Technology

Knowing what particles make up your LDL and HDL cholesterol may be important. Ion Mobility Technology provides subclass separation that will allow your healthcare provider to identify your cardiovascular risk over time. Following the change in your lipid profile as you respond to diet, exercise and possible medication to reduce your cardiovascular risk is important. Ion Mobility provides the opportunity to determine if treatment is working and if not, optimize the aggressiveness of therapy to hopefully make a difference that can be seen in the Ion Mobility measurement and graphical representation of your LDL and HDL particles. 

Cardio IQ™ Lipoprotein Fractionation, Ion Mobility 
Cardio IQ™ Lipid Panel
Cardio IQ™ Direct LDL 
Cardio IQ™ Apolipoprotein Evaluation 
Cardio IQ™ Lipoprotein (A)

Apo B

  • Apo B is a direct measurement of the number of lipoprotein particles, including LDL (“bad cholesterol”), IDL, and VLDL
  • A high Apo B number indicates increased risk for heart disease
  • Certain medications, improved eating habits, increased physical activity, and loss of body fat are some ways to
    improve Apo B

Lipoprotein (A) - Lp(a)

  • High levels of Lp(a) are associated with increased risk of cardiovascular disease and stroke
  • Lp(a) levels may be influenced by genetics. Diet and exercise have limited to no effect on lowering Lp(a); however, certain
    medications can lower levels

Cardio IQ® Apolipoprotein Evaluation - (APOLIPOPROTEIN A1, APOLIPOPROTEIN B and APOLIPOPROTEIN B/A1 RATIO)

  • Apolipoprotein A1 is the primary protein associated with HDL cholesterol. Like HDL cholesterol, increased concentrations are associated with reduced risk of cardiovascular disease. Apolipoprotein B-100 is the primary protein associated with LDL cholesterol and other lipid particles. Like LDL cholesterol, increased concentrations are associated with increased risk of cardiovascular disease. The ratio of these two apolipoproteins correlates with risk of cardiovascular disease.

Cardio IQ Advanced Lipid Panel Plus and Inflammation Panel

Measuring Lipid Subclasses using Ion Mobility

The way most doctors test for heart disease is with a lipid panel. It helps detect what HDL (good) and LDL (bad) cholesterol are, so hopefully you can reduce your risk of a possible cardiac event such as a heart attack. Nearly half of all heart attack patients were found to have no prior risk which would indicate they were heading toward an attack.

Quest Diagnostics offers advanced cardiovascular tests that help provide a more accurate and individualized picture of risk. The tests look beyond just HDL and LDL cholesterol to identify undiagnosed (or additional) risk.

These advanced cardiovascular tests, along with your lipid panel, will provide more information that you and your doctor can use to understand your complete cardiovascular health.

Lipid Subclasses as measured by Ion Mobility Technology

Knowing what particles make up your LDL and HDL cholesterol may be important. Ion Mobility Technology provides subclass separation that will allow your healthcare provider to identify your cardiovascular risk over time. Following the change in your lipid profile as you respond to diet, exercise and possible medication to reduce your cardiovascular risk is important. Ion Mobility provides the opportunity to determine if treatment is working and if not, optimize the aggressiveness of therapy to hopefully make a difference that can be seen in the Ion Mobility measurement and graphical representation of your LDL and HDL particles. 

Cardio IQ™ Lipoprotein Fractionation, Ion Mobility 

Cardio IQ™ Lipid Panel

Cardio IQ™ Direct LDL 

Cardio IQ™ Apolipoprotein Evaluation 

Cardio IQ™ Lipoprotein (A)

Apo B

  • Apo B is a direct measurement of the number of lipoprotein particles, including LDL (“bad cholesterol”), IDL, and VLDL
  • A high Apo B number indicates increased risk for heart disease
  • Certain medications, improved eating habits, increased physical activity, and loss of body fat are some ways to
    improve Apo B

Lipoprotein (A) - Lp(a)

  • High levels of Lp(a) are associated with increased risk of cardiovascular disease and stroke
  • Lp(a) levels may be influenced by genetics. Diet and exercise have limited to no effect on lowering Lp(a); however, certain
    medications can lower levels

Cardio IQ® Apolipoprotein Evaluation - (APOLIPOPROTEIN A1, APOLIPOPROTEIN B and APOLIPOPROTEIN B/A1 RATIO)

  • Apolipoprotein A1 is the primary protein associated with HDL cholesterol. Like HDL cholesterol, increased concentrations are associated with reduced risk of cardiovascular disease. Apolipoprotein B-100 is the primary protein associated with LDL cholesterol and other lipid particles. Like LDL cholesterol, increased concentrations are associated with increased risk of cardiovascular disease. The ratio of these two apolipoproteins correlates with risk of cardiovascular disease.

 

Inflammation Panel

 

hs-CRP

  • High levels of C-Reactive Protein (CRP) indicate inflammation due to infection or tissue injury
  • Modestly elevated CRP levels may be associated with increased heart disease risk. If both CRP and Lp-PLA2 levels are
    high, your risk for a heart attack or stroke increases significantly
  • Certain medications and food may have anti-inflammatory benefits

 

Lp-PLA2

  • High levels of Lp-PLA2 can predict risk of a heart attack or stroke
  • When both Lp-PLA2 levels and systolic blood pressure are high, stroke risk increases significantly
  • Certain medications can reduce levels of Lp-PLA2 

Cardio IQ® ASCVD Risk Panel with Score 

This panel provides the 10-year and lifetime risk of atherosclerotic cardiovascular disease (ASCVD) using lipid results with anthropomorphic data and family history. 
The ASCVD risk assessment is recommended in the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults.

IMPORTANT: For risk calculations to be performed, the following patient-specific information must be provided and recorded at the time of specimen collection:

  • Age: Years 
  • Gender: M (for male) or F (for female) 
  • Height Feet: Feet 
  • Height Inches: Inches 
  • Weight: lbs 
  • Race-African American: Y (for yes) or N (for no) 
  • Systolic Blood Pressure: mmHg
  • Diastolic Blood Pressure: mmHg
  • Treatment for High B.P.: Y (for yes) or N (for no) 
  • Diabetes Status: Y (for yes) or N (for no)
  • Parental History of Diab: Y (for yes) or N (for no) 
  • Smoking Status: Y (for Yes) or N (for no)

 

 


Cardio IQ® Diabetes and ASCVD Risk Panel with Scores - Includes:  Cardio IQ® Glucose; Cardio IQ® Hemoglobin A1c; Cardio IQ® Cholesterol, Total; Cardio IQ® HDL Cholesterol; Cardio IQ® Triglycerides; Cardio IQ® Non-HDL and Calculated Components; Cardio IQ® Risks and Personal Factors

If Triglyceride is >400 mg/dL, Cardio IQ® Direct LDL will be performed at an additional charge (CPT code(s): 83721).

Clinical Significance

The increasing prevalence of obesity has led to an epidemic of diabetes mellitus and related complications, including ASCVD. Prediction of the risk of ASCVD and of developing diabetes in the Cardio IQ® lab report will simplify and improve the communication of those risks to patients.

This panel provides the 10-year and lifetime risk of ASCVD events and the 8-year risk of developing diabetes. The lipid panel results will aid in the assessment of ASCVD. Assessment of 10-year risk of a first atherosclerotic cardiovascular (ASCVD) event is recommended by the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. These guidelines recommend initiating statin therapy based on 10-year ASCVD risk score. Assessment of 8-year risk of developing diabetes mellitus is based on laboratory test results with anthropomorphic data and family history. This algorithm was developed in the Framingham cohort, and is intended to aid in the identification of patients at risk for developing diabetes, permitting pharmacological or lifestyle interventions.

IMPORTANT: For risk calculations to be performed, the following patient-specific information must be provided and recorded at the time of specimen collection:

  • Age: Years 
  • Gender: M (for male) or F (for female) 
  • Height Feet: Feet 
  • Height Inches: Inches 
  • Weight: lbs 
  • Race-African American: Y (for yes) or N (for no) 
  • Systolic Blood Pressure: mmHg
  • Diastolic Blood Pressure: mmHg
  • Treatment for High B.P.: Y (for yes) or N (for no) 
  • Diabetes Status: Y (for yes) or N (for no)
  • Parental History of Diab: Y (for yes) or N (for no) 
  • Smoking Status: Y (for Yes) or N (for no)